Strategic expansion MINIject has regulatory approval in Europe for open-angle glaucoma and is pursuing US market clearance, presenting an opportunity to target eye care providers and distributors preparing for MIGS adoption in new regions.

Clinical leadership Recent leadership appointments in medical affairs and clinical operations signal a focus on evidence generation and physician engagement, enabling sales teams to align with clinical champions and key opinion leaders.

MIGS differentiation MINIject leverages a porous STAR material and supraciliary drainage to reduce intraocular pressure with a favorable safety profile, which can be positioned to glaucoma specialists as a potentially best-in-class MIGS option for patients not well served by medications alone.

Strategic partnerships Historical non-dilutive funding and collaboration with AbbVie indicate a path for co-development or distribution partnerships, suggesting outreach to large medtech distributors and pharma/device collaborators.

Early market traction Launchs in the Netherlands and initial implantations demonstrate early adopter activity; sales efforts can target regional ophthalmology centers and private clinics with MIGS programs to accelerate adoption and gather real-world outcomes.